文献速递外周动脉疾病

症状性外周动脉疾病血运重建:VOYAGER PAD试验的外部适用性

Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-12-16

在丹麦全国血管注册登记(DVR)2000—2016年因症状性外周动脉疾病(PAD)行下肢血运重建的32 911例患者中,27.1%符合VOYAGER PAD试验入组标准。不符合者中30.7%至少存在一条排除标准、42.3%不满足纳入标准。符合者在多数终点上的三年累积发生率高于VOYAGER PAD试验对照组。

要点

  • 常规实践中27.1%的症状性PAD血运重建患者符合VOYAGER PAD入组标准。
  • 不符合者中30.7%存在至少一条排除标准,42.3%不满足纳入标准。
  • 符合者较试验参与者年龄更大、血管症状更重、出血风险更高、预后更差。

核心结论

  • 常规临床实践中27.1%的患者符合VOYAGER PAD试验入组标准,这些患者较试验参与者年龄更大、血管症状更重、出血风险更高且预后更差。

研究设计与样本

  • 基于丹麦全国血管注册登记(DVR)2000—2016年因症状性PAD行下肢血运重建的32 911例患者,应用VOYAGER PAD试验纳入与排除标准并估计主要与次要终点的三年累积发生率。

主要发现

  • DVR中27.1%的PAD患者为「VOYAGER符合」;未纳入者中30.7%至少存在一条排除标准(「VOYAGER排除」),另有42.3%不满足纳入标准(「VOYAGER未纳入」)。
  • 主要排除原因包括心房颤动32.3%、血压控制不佳的高血压20.6%、需要长期双联抗血小板治疗10.9%、细胞色素P450抑制剂或诱导剂9.7%、肾功能衰竭9.3%。
  • 主要疗效终点的三年发生率在「VOYAGER符合」为10.08/100人年、「VOYAGER排除」为16.32/100人年、「VOYAGER未纳入」为6.98/100人年。
  • 主要安全终点TIMI大出血发生率分别为「VOYAGER符合」2.24/100人年、「VOYAGER排除」3.76/100人年、「VOYAGER未纳入」1.17/100人年。
  • 「VOYAGER未纳入」患者(主要因中心性主髂动脉手术)的次要终点发生率也持续较低,「VOYAGER排除」患者最高;「VOYAGER符合」患者多数终点的累积发生率高于VOYAGER PAD试验对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the VOYAGER PAD trial, rivaroxaban 2.5 mg plus aspirin significantly reduced the primary composite efficacy outcome of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death compared with aspirin alone. However, patients enrolled in the trial may not reflect patients encountered in daily clinical practice. This study described the proportion of patients eligible for VOYAGER PAD within the nationwide Danish Vascular Registry (DVR), reasons for ineligibility, and outcomes according to eligibility. METHODS: In total, 32 911 patients who underwent lower extremity revascularisation for symptomatic peripheral arterial disease (PAD) in the DVR (2000-2016) were identified. Trial inclusion and exclusion criteria were applied, and the three year cumulative incidence of primary and secondary trial outcomes was estimated. RESULTS: Altogether, 27.1% of patients with PAD in the DVR were "VOYAGER eligible". Of those not included, 30.7% had at least one exclusion criterion ("VOYAGER excluded"), and an additional 42.3% did not fulfil the inclusion criteria ("VOYAGER not included"). The main reasons for exclusion were atrial fibrillation (32.3%), poorly regulated hypertension (20.6%), requirement for long term dual antiplatelet therapy (10.9%), cytochrome P450 inhibitors or inducers (9.7%), and renal failure (9.3%). The three year rate of the primary efficacy outcome was 10.08 per 100 person years among the "VOYAGER eligible", 16.32 among "VOYAGER excluded", and 6.98 among the "VOYAGER not included". For the primary safety outcome of thrombolysis in myocardial infarction (TIMI) major bleeding, rates were 2.24, 3.76, and 1.17, respectively. Rates of secondary endpoints were also consistently lower for patients who did not meet the inclusion criteria (predominantly due to central aorto-iliac procedures) and highest for "VOYAGER excluded" patients. "VOYAGER eligible" patients experienced a higher cumulative incidence of most endpoints than patients enrolled in the control arm of the VOYAGER PAD trial. CONCLUSION: Among patients in routine clinical practice, 27.1% were eligible for the VOYAGER PAD trial. These patients were older, had more severe vascular symptoms, higher bleeding risk, and worse prognosis than trial participants.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Søgaard M, Nielsen PB, Skjøth F, et al. Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. Eur J Vasc Endovasc Surg. 2021. PMID: 34924303. doi:10.1016/j.ejvs.2021.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。